The low therapeutic index of established antiepileptic drugs coupled with a better understanding of the pathophysiology of seizure production has led to the development of a range of new therapeutic agents for the treatment of epilepsy. In this review, the three drugs recently licensed in the UK (vigabatrin, lamotrigine and gabapentin) are profiled, together with several of the more promising up-and-coming cofilpounds (oxcarbazepine, felbamate, tiagabine, stiripentol, remacemide and topiramate). Future avenues for clinical research in the pharmacological management of the epilepsies involve their rational use both singly and in combination.
INTRODUCTION
Epilepsy is a common condition with a point prevalence of just under 1% of a given population 1. There are, by implication, around 500 000 people in the UK alone who have epileptic seizures, fewer than 70% of whom will have them fully controlled with the currently available antiepileptic drugs 2. Many patients, particularly those with underlying anatomical lesions, respond poorly to monotherapy and are treated with combinations of anticonvulsants that often cause disabling side-effects with only an outside chance of significantly improved seizure control.
Dose-related side-effects and idiosyncratic reactions are all too common with existing anticonvulsants. The tendency to produce headache, nausea, dizziness, drowsiness, cognitive impairment and other central nervous system side-effects is almost universal 2. Their potential for teratogenicity 3'4 and for deleterious drug interactions 5 make their long-term use problematical. The last few years have been exciting times for epileptologists. There has been a rush of interesting new antiepileptic drugs into clinical development.
THE BASIS OF SEIZURES
Histologically, epileptic neuronal tissue often shows only non-specific changes such as gliosis or dendritic degeneration 6'7. The biochemical interplay at the site of epileptogenesis is more interesting, and an understanding of the pathogenesis may lead us to alter successfully the subtle biochemical imbalances responsible for seizure generation and propagation. Recent advances in drug development have focused on the therapeutic potential of manipulating brain neurotransmitters.
Endogenous substances such as gamma aminobutyric acid (GABA), adenosine and glycine are thought to be of importance in inhibiting seizure spread 7. Stimulation of the GABAA receptor results in an influx of chloride ions, stabilizing the neuronal membrane and preventing seizure activity. Work in primates has demonstrated a selective loss of such terminals in epileptogenic foci s, implying a local deficit in inhibition. There is decreased binding, also, to the GABA/benzodiazepine receptor complex in temporal lobe lesions 9.
The role of the excitatory amino acids, especially glutamate and aspartate, has been well recognized for a number of years. Receptors for these and other dicarboxylic acids are present in altered density in patients with either generalized 1° or temporal lobe 11 seizures. This implicates the excitatory system in producing a micro-environment conducive to epileptogenesis. These processes and their interplay are important factors in determining the extent of the neurological instability underlying the ictal diathesis 12.
ESTABLISHED ANTICONVULSANTS
The last two first-line anticonvulsants to be introduced in the UK were carbamazepine in 1967 and sodium valproate in 1974. These are still the best drugs for controlling most types of seizures. There remains, however, a great deal of scope for improving our treatment of epilepsy. Fewer than 70% of patients are adequately controlled with antiepileptic monotherapy 13. The addition of a second or third drug will provide substantial improvement in only around 10% of the remainder 2. The more antiepileptic drugs the patient takes, the greater the incidence of adverse effects, particularly cognitive impairment and teratogenesis.
The modes of action of established antiepileptic drugs are,multiple, complex and overlapping TM. Their effects on the central nervous system are widespread and rather indiscriminate--a neuropharmacological blunderbuss rather than a laser! The introduction of three new anticonvulsants with novel mechanisms of action in the UK over the last 5 years has revolutionized our approach to refractory epilepsy. Vigabatrin, lamotrigine and gabapentin have led the way for a plethora of newer agents that are being extensi.vely tested in scienificallybased studies world-wide.
This review will deal with the compounds that are breaking through in the routine management of epilepsy, and will focus also on the most promising drugs currently undergoing clinical trials. The pharmacological profiles of the anticonvulsants featured in this paper are summarized in Table 1 . Their potential ranges of efficacy are outlined in Table 2 .
NEW ANTIEPILEPTIC DRUGS Vigabatrin
Vigabatrin was licensed in the UK for use as add-on therapy for refractory epilepsy in 1989. It is being increasingly used in Europe, Africa and Asia, but still awaits regulatory approval in North America.
Mode of action
Vigabatrin is a GABA analogue which acts as a 'suicide' inhibitor of GABA-transaminase (Fig. 1) . It binds irrevocably to its target enzyme, and so facilitates GABA-ergic inhi- 
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Pharmacokinetics and interactions
Vigabatrin is well absorbed after oral administration, with peak concentrations occurring around 3 hours after dosing 17. Although it is given as a racemic mixture, only the S-enantiomer has a significant pharmacological effect. OH dizziness, headache, diplopia, ataxia and vertigo reported in approximately 2% 21 . Tolerance to vigabatrin's sedative effects can be expected 26. Psychiatric problems following its introduction, such as anxiety, depression and aggression are well recognized. The precipitation of psychosis at high dosage or following its sudden withdrawal contraindicates vigabatrin's use in patients with a history of behavioural disturbance 21. Accordingly, initial dosing should be low (0.5-1 g daily) with careful titration to a maximum of 2-3 g daily in the majority of patients 27.
Lamotrigine
Folic acid was shown to have proconvulsant properties in the mid-1960s. Accordingly, antiepileptic drug development at the Wellcome Institute concentrated on folate antagonism as a method of identifying potential new antiepileptic drugs. Lamotrigine was born out of this search, although it is now known that these properties are not linked.
Mode of action
Lamotrigine is chemically and functionally unrelated to the other antiepileptic drugs (Fig.  2) . Its anticonvulsant effect arises from a blockade of sodium channels, limiting the presynaptic release of glutamate and aspartate and, thus, stabilizing neuronal membranes 2s. This, however, is unlikely to be the whole story 29
Pharmacokinetics and interactions
Oral administration of lamotrigine leads to its rapid and near complete absorption. The elimination half-life is around 29 hours with metabolism largely by hepatic glucuronidation 3°. Interestingly, patients with Gilbert's disease have a longer half-life due to a decrease in the activity of the enzyme bilirubin uridine diphosphate glucuronyl transferase 31.
Lamotrigine does not itself induce or inhibit hepatic enzymes. Consequently, it has no influence on the metabolism of other lipid soluble drugs, including the oral contraceptive pill and warfarin. Sodium valproate has been shown to lengthen its half-life to around 59 hours, and the enzyme-inducing anticonvulsants, carbamazepine, phenytoin and phenobarbitone reduce it to around 12 hours 32. There have been reports of symptoms of neurotoxicity (headache, nausea, dizziness, diplopia, ataxia) in patients taking carbamazepine in whom lamotrigine has been introduced 33. These disappear when the dose of either drug is reduced. This is thought to be the clinical representation of a pharmacodynamic interaction 34. Sedation is not a prominent manifestation of lamotrigine toxicity 49. Double-blind trials to assess the usefulness of lamotrigine as monotherapy, using carbamazepine and phenytoin as comparators have just been completed. Preliminary results suggest equal efficacy to carbamazepine and phenytoin with better tolerability. Other comparative studies in children, in the primary generalized epilepsies and in the elderly are underway. The starting dose and titration rate will depend on existing treatment s° when the drug is used as adjunctive therapy (Table 3) . Lamotrigine is usually prescribed twice daily, but a single daily dose can be used if the drug is combined with sodium valproate or as monotherapy. A low, slow introduction schedule will reduce the likelihood of rash.
Efficacy and tolerability
Ten double-blind, placebo-controlled, add-on studies have been carried out with lamotrigine 35-44, nine of which reported success against partial seizures with or without secondary generalization. Many open studies have confirmed these findings 4s. Clinical experience also suggests that lamotrigine is effective for the primary generalized epilepsies 46. There is anecdotal evidence too to support its value in Lennox-Gastaut syndrome 47. These observations have not yet been substantiated in controlled clinical trials.
Lamotrigine is a well-tolerated drug, with skin rash being the most common reason for withdrawal. This occurs in approximately 3% of patients and depends on the rate of introduction of the drug 4s. Side-effects such as dizziness, headache, nausea and vomiting, ataxia, diplopia and tremor are other minor problems associated with lamotrigine administration. 
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[ I Gabapentin, a chemical analogue of GABA, was intended to act as a GABA agonist (Fig. 3) . It was thought too that, being hydrophilic, blood-brain barrier penetration would be facilitated. 
Mode of action
Oxcarbazepine Interestingly, the anticonvulsant properties of gabapentin are not dependent on any direct action on the GABA-ergic system 51. The drug appears to bind to a membrane site near the glutamate receptor, which may represent a transport system for L-amino acids 52'53. A recent study suggests that gabapentin may also limit the rate of firing of sodium-dependent action potentials 54.
gabapentin's efficacy against partial seizures 5s. A clear-cut dose-response relationship in reducing partial and secondary generalized seizures has been demonstrated with the drug 59. In a large double-blind, parallel group, placebo-controlled study involving 127 patients with drug-resistant partial seizures, 25% of these taking gabapentin experienced a reduction in seizure frequency exceeding 50% 6°. The therapeutic effect of gabapentin has been shown to persist for up to 24 months 6~.
Adverse
The recommended schedule for prescribing gabapentin involves thrice daily administration. However, some patients appear to respond to a morning and evening dose. The drug should be introduced over the first week at low dosage (e.g. 300 mg twice daily) and thereafter can be increased more rapidly as necessary to a maximum of 2700 mg daily or thereabouts. Its use is not currently recommended in children under 12 years of age.
Pharmacokinetics and interactions
Oral dosing of gabapentin results in rapid absorption, and the drug has a bioavailability of 60%. A saturable transport mechanism in the gut explains the lack of proportionality between increased doses and levels in plasma 55. Maximum concentrations occur 2-3 hours after administration and the elimination halflife approximates 5-7 hours B6. There is no significant protein binding, and the drug is excreted unchanged in the urine with clearance rates equivalent to those for creatinine. The lack of important drug interactions with gabapentin has been widely reported 57.
Efficacy and tolerability
A small, dose-ranging, double-blind cross-over study was the first to provide evidence for 0/'~ NH 2 Oxcarbazepine, the 10-keto analogue of carbamazepine (Fig. 4) , has been licensed for use in a number of countries worldwide. Its metabolism differs from that of the parent compound and this holds out the possibility of a more benign side-effect profile with fewer drug interactions 64.
Mode of action
The mode of action of oxcarbazepine is similar but not identical to that of carbamazepine 65. Its major effect, therefore, is in preventing burst firing of neurones by blocking voltagedependent sodium channels.
Pharmacokinetics and interactions
Oxcarbazepine is a pro-drug, the main active principle being 10,11-dihydro-10-hydroxy-carbamazepine which is largely eliminated by hepatic glucuronidation 63. This moiety is 55% bound to.plasma proteins and has an elimination half-life approximating 9 hours. Unlike carbamazepine, oxcarbazepine does not undergo autoinduction of metabolism 66. The drug has no effect on the metabolism of other anticonvulsants 67. However, the area under the concentration-time curve of the active metabolite is lower in patients taking carbamazepine, phenytoin and phenobarbitone than in controls suggesting a small, probably clinically irrelevant, induction effect of these drugs on its elimination 67'6s.
Oxcarbazepine has less potential than carbamazepine to induce liver enzymes and so influence the metabolism of other drugs. It appears to induce selectively a single isoform of cytochrome P450, namely IIIA 69. Volunteer studies have suggested that it does not interfere with warfarin metabolism 7°, nor will cimetidine 71 or dextropoxyphene 72 inhibit its breakdown. However, decreased bioavailability of the oral contraceptive pill has been noted in some patients treated with oxcarbazepine 73.
Efficacy and tolerability
Several double-blind, add-on studies have confirmed comparable efficacy between oxcarbazepine and carbamazepine 74-76. In addition, no difference in anticonvulsant effect was found between oxcarbazepine and carbamazepine in patients with newly diagnosed epilepsy 77. Like carbamazepine, oxcarbazepine has no place in the treatment of absence seizures and myoclonic jerks 69.
Comparisons with carbamazepine have suggested a lower incidence of minor sideeffects 7~-77. Those most commonly associated with oxcarbazepine are diplopia, nausea, headache, dizziness, drowsiness and ataxia 69.
Oxcarbazepine, like carbamazepine, has a propensity to cause hyponatraemia in some patients 7s. However, it produces fewer rashes than carbamazepine 79 and perhaps other idiosyncratic reactions 69.
Felbamate
Felbamate is a dicarbamate derivative (Fig. 5) which is licensed in the United States and has recently gained approval for use in partial seizures and Lennox-Gastaut syndrome in some European countries. It has been reported in animal models as having an unique profile of anticonvulsant activity, with little tendency to cause neurotoxicity s°. 
Mode of action
Felbamate has an interesting effect in decreasing the binding of ligands at the glycine site of the n-methyl-d-aspartate (NMDA) receptor sl. This implies that it may act as a glycine antagonist, possibly diminishing the deleterious influence on neuronal function of excitatory amino acids. Several other modes of action have also been suggested s2.
Pharmacokinetics and interactions
Oral administration of felbamate leads to complete and rapid absorption. Following a single dose, the half-life ranges between 14 and 22 hours in epileptic patients s2. A proportion of absorbed drug is excreted unchanged in the urine, with the rest undergoing hydroxylation and conjugation in the liver.
On addition of felbamate, phenytoin, valproate and phenobarbitone levels will rise by around 20-30%, whereas serum carbamazepine will fall by a similar amount s3. However, this latter effect is offset by greater production of the active metabolite, carbamazepine 10,11 epoxide s4. Enzyme-inducing antiepileptic drugs will increase the rate of clearance of felbamate sS. The effect of valproate on felbamate levels is less clear-cut s6.
Efficacy and tolerability
The efficacy of felbamate has been established in six major clinical trials involving around 370 patients 8~-92. Five of these were undertaken in patients with partial seizures with or without secondary generalization. The final piece of evidence consists of a major placebocontrolled trial in 73 children with LennoxGastaut syndrome, each of whom had at least 90 atonic or atypical absence seizures per month despite treatment with one or two established antiepileptic drugs. Felbamate reduced the frequency of atonic seizures as well as atypical absences 9°. Preliminary results in the primary generalized epilepsies are also promising. Long-term efficacy data with the drug, however, are still limited, although early observations are encouraging 93.
The most frequent side effects with felbamate originate from the central nervous system and include diplopia, dizziness, headache, nausea and vomiting, diarrhoea and ataxia s2. Weight loss of around 5% body weight has been reported in some patients, probably secondary to anorexia and nausea. Both insomnia and somnolence have been associated with felbamate administration s3.
Tiagabine
Tiagabine, a nipecotic acid derivative (Fig. 6) , has a powerful anticonvulsant effect in animal seizure models 94. 
Mode of action
Tiagabine acts by inhibiting GABA re-uptake by glial cells and presynaptic neurones 95. The resultant increase in synaptic GABA concentrations is thought to be responsible for its anticonvulsant action 96.
Pharmacokinetics and interactions
Tiagabine is well-absorbed orally with peak levels occurring around an hour after dosing 94.
The elimination half-life varies between 4 and 13 hours. Elimination is mainly by hepatic metabolism, which appears not to be influenced by concomitant anticonvulsant treatment.
Efficacy and tolerability
Double-blind studies suggest useful efficacy for tiagabine against partial and secondary generalised seizures 97'9s. Monotherapy trials are also currently being undertaken 99. Side-effects so far have been largely confined to headache, dizziness and sedation.
Remacemide
Remacemide was designed to affect the excitatory component of epileptogenesis. It has recently entered phase III clinical trials in epileptic patients.
Mode of action
Remacemide is chemically unrelated to any other anticonvulsant (Fig. 7) and has been shown to be a weak, non-competitive NMDA antagonist 1°°. At least part of remacemide's anticonvulsant action is thought to be due to its main metabolite, the desglycinate.
Pharmacokinetics and interactions
Oral dosing of healthy volunteers shows absorption to be rapid, peak levels being attained around 1 hour after administration. The parent drug has an elimination half-life approximating 4 hours, whereas the active desglycinate metabolite has a longer half-life --N ~NH 2HCI Fig. 7 : Structure of remacemide.
in the region of 12-18 hours l°°. This difference in pharmacokinetics between parent drug and active metabolite is important in determining the optimum frequency of dosing.
Though not yet complete, interactions studies with remacemide suggest that it may act as an enzyme inhibitor, slowing the metabolism of both phenytoin and carbamazepine ~°1. Clearance of remacemide is increased in patients taking phenytoin and carbamazepine compared with those treated with sodium valproate 1°2.
Efficacy and to/erabi/ity
Preliminary results with remacemide suggest useful efficacy against partial and secondary generalized seizures 1°3'1°4. In common with other centrally acting drugs, lightheadedness, diplopia and dizziness have been reported as well as gastro-intestinal symptoms such as dyspepsia, nausea and vomiting. Aggressive behaviour has been noted on rare occasions. No evidence of idiosyncratic reaction to the drug has so far emerged.
Stiripentol
Mode of action
No precise mechanism of action has been determined, but laboratory studies suggest that stiripentol increases GABA levels either by inhibiting synaptosomal uptake or by decreasing its metabolism l°s
Pharmacokinetics and interactions
The drug is slowly distributed rendering its elimination curve multiphasic. It is highly protein bound and undergoes non-linear kinetics 1°9. Stiripentol is biotransformed mainly by hepatic metabolism H°, and this can be accelerated by other antiepileptic drugs 111. It strongly inhibits the metabolism of other anticonvulsants, causing a rise in concomitant phenytoin, carbamazepine, sodium valproate and phenobarbitone112,113
Efficacy and to/erabi/ity
Most of the studies carried out so far have been open label design in patients with partial seizures with or without secondary generalization111,114. A preliminary report supports efficacy in children with atypical absences 115. Overall, stiripentol is well tolerated with only ataxia, nausea, vomiting and lethargy currently complicating its clinical use.
Topiramate Topiramate (Fig. 9 ) is yet another antiepileptic compound, which is structurally distinct from all other comparable drugs! Stiripentol (Fig. 8) 
New antiepileptic drugs
Mode of action
As with many of the new anticonvulsants, this is presently uncertain. One study suggests that it may enhance GABA-mediated chloride ion influx ll6.
Pharmacokinetics and interactions
Topiramate is slowly absorbed after oral dosing, peak concentrations in plasma occurring between 1 and 4 hours after administration. The drug is excreted largely unchanged in the urine, with an elimination half-life ranging from 19 to 23 hours 11~. Around 5~ of a dose undergoes hepatic metabolism. Interactions with other anticonvulsants have still to be fully delineated.
Efficacy and tolerability
A number of double-blind, placebo-controlled studies have been completed with topiramate in adults with refractory partial seizures with or without secondary generalization ~ls'~m These have shown a good response (defined as a reduction of >50c~ in seizure frequency) in more than half of the patients taking more than 200 mg of the drug per day ~2°" v~l. Preliminary data also suggest efficacy in the LennoxGastaut syndrome ~2'~. Topiramate appears likely to be a valuable add-on treatment in refractory epilepsy ~23. The most frequently reported side-effects with topiramate include ataxia, cognitive dysfunction, dizziness, headache, nausea, nystagmus, tremor and visual disturbance. Less common problems include mood lability and weight loss. Animal toxicity studies suggest that topiramate may be teratogenic.
CONCLUSIONS
The recent developments in the pharmacotherapy of epilepsy are providing formidable challenges to the clinician. Which patients should receive which drug and for which seizure type? So far, most is known about lamotrigine and vigabatrin, as these have been in general use for some years. Felbamate and gabapentin have been licensed more recently in the USA and approved for licensing in some European countries. Oxcarbazepine, also generally avail-13 able in some countries, appears to be better tolerated than carbamazepine. These drugs are undoubtedly valuable in the treatment of refractory epilepsy. The early clinical promise of tiagabine and remacemide are indicators that these compounds too will make the transition from interesting chemicals to useful therapeutic agents. Stiripentol and topiramate show a few more problems, but may well prove valuable as second-line therapy in refractory epilepsy. The drugs touched on in this review are merely the tip of a growing iceberg.
For an antiepileptic drug to demonstrate efficacy in refractory epilepsy is impressive. Their use as adjunctive therapy, however, is likely to exaggerate their side-effect profiles. The level playing field of double-blind, controlled trials in previously untreated patients will demonstrate the true worth of these new drugs in comparison with the much less expensive and more established compounds. Monotherapy may well prove the newer crop of anticonvulsants more benign. So far, only felbamate has been licensed for this indication, although lamotrigine is likely to be available soon as monotherapy in Europe.
The ultimate goal for everyone involved in the development of antiepileptic drugs is the discovery of effective and safe agents with well-defined mechanisms of action. We may find it a useful strategy to combine drugs that independently influence either excitatory or inhibitory processes. As time passes, the best combinations are likely to be discovered serendipitously. The use of two agents acting on the 'same side of the fence', such as vigabatrin and tiagabine, may be a logical approach in refractory single seizure types. Those with different modes of action, such as vigabatrin and lamotrigine, may be best combined for patients experiencing more than one seizure type. A narrower range of biochemical effects may lead to enhanced tolerability during such dual therapy, and 'selective' co-prescribing could be the key to improving seizure control with fewer side effects. This approach should supersede the current empiricism, and lead to the rational evolution of combination therapy for the treatment of refractory epilepsy.
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